Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ) (XVIPY) Stock Overview
Explore Xvivo Perfusion AB (publ)’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
945M
P/E Ratio
43.89
EPS (TTM)
N/A
ROE
0.10%
XVIPY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Xvivo Perfusion AB (publ) (XVIPY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $14.98.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 43.89 and a market capitalization of 945M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Christoffer Rosenblad
170
MAessans gata 10, Gothenburg
2022